The clinical stage Specialty Biopharmaceutical Company is focused on developing therapies for the top 5 dermatology & skin care conditions, which represent a $12.9 Billion Rx market and a $121 Billion skin care market. MatriSys Bio's lead microbiome Phase I/II clinical program addresses the Atopic Dermatitis market with 15 M US patients (132 M worldwide), and is NIH funded, and IP protected with an exclusive license from UCSD. The company's "Good Bug," S. hominis, is highly potent against the "Bad Bug," Staph. aureus, which has long been associated with AD. S. hominis does not affect other "Good Bugs," leading to the natural rebalance of the skin microbiome.